Company Overview and News

FBM KLCI notches limited gains as region stays muted

2018-10-01 theedgemarkets
KUALA LUMPUR (Oct 1): The FBM KLCI notched up limited gains at the midday break today as decliners overtook advancers, against the backdrop of mixed regional markets.
APEXF 7084 7090 BATS 4162 0082 1163 5268 5256 6033 5199 0020 5843 0176 PNADF 1201 3301 7108 1899 2836 HIPEF PNAGF

KLCI pares loss, broader sentiment stays weak

2018-09-03 theedgemarkets
KUALA LUMPUR (Sept 3): The FBM KLCI pared some of its losses at midday break today, as the broader sentiment stayed negative, in line with the drop at regional markets.
HLFBF SPMXF 5071 7036 1082 0096 3794 9334 7123 0020 5199 SPMXY 5819 2836 HIPEF 1929

Spectre of September ghosts keep haunting KLCI

2018-09-03 theedgemarkets
KUALA LUMPUR (Sept 3): The FBM KLCI remained in negative zone at mid-morning today as key index-linked blue chips retreated, in tandem with most regional markets.
HLFBF UPBMF 1082 5681 BATS 4162 0096 2089 9334 6033 7123 0020 5199 PNADF 7129 6888 AXXTF HIPEF PNAGF

KLCI claws into positive territory as Tenaga lifts

2018-08-03 theedgemarkets
KUALA LUMPUR (Aug 3): The FBM KLCI clawed into positive territory at the midday break today, lifted by gains at Tenaga Nasional Bhd and other select blue chips.
HLFBF 7172 2089 5014 0020 2852 KLKBY 5347 3867 TNABY MYTEF PNAGF UPBMF 1082 7765 6033 5139 2445 PNADF 4863 6645 0900 5819 MYPRY TNABF

KLCI retreats as TM, select blue chips drag

2018-08-03 theedgemarkets
KUALA LUMPUR (Aug 3): The FBM KLCI retreated at mid-morning today, dragged by losses at Telekom Malaysia Bhd (TM) and other select blue chips, against the backdrop of a set of tentative regional markets.
HLFBF UPBMF 1082 7113 5681 TPGVF 5015 2089 0020 TGLVY 4863 3867 0126 5517 5819 MYTEF 2836

Bursa slides at opening

2018-06-14 malaymail
KUALA LUMPUR, June 14 — Bursa Malaysia opened lower today in line with regional markets and weighed down by selling activities in heavyweights.
PBLOF 8789 1295 BSMAF 7123 1818 0020

Related Articles

ALIM: Alimera Sciences Analysis and Research Report

2018-10-01 - Asif

Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...

DMPI: DelMar Pharmaceuticals Analysis and Research Report

2018-09-25 - Asif

Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...